To ascertain the role of ADAM17 in doxorubicin-induced cardiomyopathy, we selected A17fl/fl and A17α-MHCKO male mice at 8 weeks of age and injected doxorubicin into these mice in the second proportion of in vivo experiments (Fig. 2a). This evidence concerns the gene ADAM17 and cardiomyopathy.